Is setmelanotide FDA-approved, and what does the research show?

What is setmelanotide?

Setmelanotide is a man-made peptide of eight amino acids joined into a ring ¹. It is an analog, a close chemical relative, of alpha-melanocyte-stimulating hormone, or alpha-MSH, a hormone the body makes itself ¹. FDA's label calls it "a melanocortin 4 (MC4) receptor agonist," meaning a molecule that switches on the MC4 receptor ¹. That receptor sits on brain cells involved in "regulation of hunger, satiety, and energy expenditure" ¹. Its maker, Rhythm Pharmaceuticals, holds the U.S. approval for it as Imcivree, a solution injected under the skin ¹, ².

Setmelanotide is not a general weight-loss drug ¹. The MC4 receptor is part of the leptin-melanocortin pathway, a chain of signals that helps regulate body weight ³. Severe obesity that begins in early childhood can be caused by variants in both copies of genes that affect that pathway ³. FDA approved it only for obesity with a few rare causes, each tied to a fault in that pathway, and the label's limitations of use exclude general obesity ¹.

Is setmelanotide FDA-approved?

Yes, for a narrow set of patients. The label says Imcivree is "indicated to reduce excess body weight and maintain weight reduction long term" in two groups ¹. The first is adults and children aged 4 and older with acquired hypothalamic obesity ¹. That is obesity that follows "hypothalamic injury or dysfunction," such as a tumor of the hypothalamus ¹, ⁴. The second is people aged 2 and older with "syndromic or monogenic obesity," obesity caused by a genetic syndrome or by a fault in a single gene, due to Bardet-Biedl syndrome or to POMC, PCSK1 or LEPR deficiency "confirmed by genetic testing" ¹.

Those names are genes and the proteins they make. POMC is pro-opiomelanocortin; PCSK1 is proprotein convertase subtilisin/kexin type 1; LEPR is the leptin receptor ¹. The trials enrolled people with variants in both copies of one of these genes, "homozygous or presumed compound heterozygous" in the label's words ¹. Bardet-Biedl syndrome is a rare genetic disease marked by extreme hunger, called hyperphagia, and severe obesity from early childhood ⁵. In all of these conditions, the label says, obesity is "associated with insufficient activation of the MC4 receptor" ¹.

The label's limitations of use draw the line for everyone else. Imcivree "is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective" ¹. The first is obesity from a suspected deficiency whose gene variants are "classified as benign or likely benign" ¹. The second is "Other types of obesity not related to acquired HO [hypothalamic obesity], BBS [Bardet-Biedl syndrome], or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity" ¹. The label also reports that "Short-term administration of IMCIVREE in 12 otherwise healthy patients with obesity increased resting energy expenditure," then adds that "IMCIVREE is not approved to treat such patients" ¹.

FDA's Drugs@FDA record lists Rhythm's new drug application, NDA 213793, approved November 25, 2020 ². Its marketing status is "Prescription" as of November 6, 2026, the date of its data ². The approval letter covered "chronic weight management in adult and pediatric patients 6 years of age and older" with the three genetic deficiencies ⁶. Three later approvals widened it: Bardet-Biedl syndrome on June 16, 2022, children aged 2 to under 6 on December 20, 2024, and acquired hypothalamic obesity on March 19, 2026 ², ⁷, ⁸, ⁹. It is available only on prescription ², and for the genetic deficiencies the label requires a diagnosis confirmed by genetic testing ¹.

See the FDA status of every peptide, updated weekly.

How does setmelanotide work?

Setmelanotide switches on the MC4 receptor, with "20-fold less activity" at two related receptors, MC3 and MC1 ¹. The label says that "based on nonclinical evidence," meaning animal and laboratory work, the drug "may re-establish MC4 receptor pathway activity" ¹. That would "reduce food intake and promote weight loss through decreased caloric intake and increased energy expenditure" in the approved conditions ¹. In people, the trials measured weight and a daily hunger score rather than the pathway itself ³, ¹.

The MC1 receptor explains the drug's most visible effect. It "is expressed on melanocytes," the skin's pigment cells, and switching it on "leads to accumulation of melanin and increased skin pigmentation independently of ultraviolet light" ¹. Skin darkening is therefore a direct effect of the drug, one that occurs without sun exposure ¹.

What does the research show?

Studied in people with POMC, PCSK1 or LEPR deficiency: two single-arm, open-label, multicenter phase 3 trials, the large trials that come before approval, published online October 30, 2020 ³. Single-arm and open-label mean everyone received setmelanotide and knew it, so the main results have no placebo comparison ³. They enrolled people aged 6 or older with obesity and genetically confirmed or suspected deficiency ³, ¹.

After 12 weeks of open treatment, those who had lost at least 5 kilograms (or 5 percent, if under 100 kilograms) went on ³. They entered an 8-week withdrawal, four weeks of drug and four of placebo in an order neither they nor their doctors knew, then 32 more weeks of open treatment ³. The primary endpoint, the main result the trial was designed to test, was the share of participants losing at least 10 percent of their weight at about one year ³. Ten people entered the POMC trial and 11 the LEPR trial ³.

Eight of the ten (80 percent) in the POMC trial and five of the 11 (45 percent) in the LEPR trial reached the 10 percent mark ³. The label puts the mean weight change at one year at 23.1 percent lost in the POMC or PCSK1 trial and 9.7 percent in the LEPR trial ¹. In seven people per trial with hunger data, the "most hunger" score fell by a mean of 27.1 percent and 43.7 percent ³.

Switched to placebo for four weeks, the 16 who had lost weight regained an average of 5.5 kilograms in the POMC or PCSK1 trial and 5.0 in the LEPR trial ¹. They lost weight again on restarting the drug ¹. The label counts 27 people in these trials, six of whom had not reached one year at its data cutoff and are not in the efficacy figures ¹.

Studied in people with Bardet-Biedl syndrome: one phase 3 trial, published online November 7, 2022 ⁵. It was randomized, double-blind and placebo-controlled for its first 14 weeks, then open-label to 52 weeks of treatment ⁵. Randomized means chance assigned each person to drug or placebo; double-blind means neither they nor their doctors knew which ⁵. It enrolled people aged 6 and older with obesity and Bardet-Biedl syndrome or Alström syndrome, a second rare genetic disease ⁵.

It randomized 38 people, 32 with Bardet-Biedl and six with Alström syndrome ⁵. The primary endpoint was at least 10 percent weight loss after 52 weeks of the drug in those aged 12 or older ⁵. It was met by 32.3 percent of the 31 aged 12 or older in the analysis set, which held both conditions (95 percent confidence interval 16.7 to 51.4) ⁵. A confidence interval is the range within which the true figure most likely lies. Every one who met it had Bardet-Biedl syndrome; none of the three with Alström syndrome in that set did ⁵.

Over the 14 placebo-controlled weeks, body weight in those aged 12 or older fell 2.4 percent on the drug and 0.3 percent on placebo ⁵. That difference of -2.1 percentage points did not reach statistical significance, the usual test that a difference is unlikely to be chance, with a confidence interval of -4.6 to 0.4 ⁵. Hunger moved sooner: 71.4 percent on the drug had cut their maximal hunger score by at least a quarter at week 14, against 20.2 percent on placebo ⁵. Hunger was scored daily by those aged 12 and older, on a scale from 0 to 10 ¹, ⁵.

The label describes the same trial in a larger group, 44 people with Bardet-Biedl syndrome across its cohorts ¹, ⁵. Its figures are BMI (body mass index, weight against height) in those 44 ¹. The paper's are body weight in those aged 12 or older among its randomized 38, so the two sets of numbers differ ¹, ⁵. In the 44, BMI fell 4.6 percent on the drug and 0.1 percent on placebo at 14 weeks ¹. The placebo-adjusted difference of -4.5 percentage points, confidence interval -6.5 to -2.5, is one the label calls statistically significant ¹.

After 52 weeks of drug in 31 people, BMI fell a mean of 7.9 percent; 61.3 percent lost at least 5 percent and 38.7 percent at least 10 percent ¹. The label also saw numeric improvements in blood pressure, lipids and waist size, but says that "because of the limited number of patients studied and the lack of a control group, the treatment effects on these parameters could not be accurately quantified" ¹.

Studied in people with acquired hypothalamic obesity: one phase 3 trial, published in the journal's July 9, 2026 issue ⁴. It randomized participants two to one to the drug or placebo, double-blind, for 52 weeks after a dose-escalation period ⁴. The label reports 142 people aged 4 and older randomized and analyzed, 47 percent of them adults, with a mean BMI of 36 ¹. The published paper reports 120 participants, 81 assigned to the drug and 39 to placebo ⁴. The label counts all 142 randomized and treated; the paper reports the trial's planned pivotal cohort, "the first 120 participants dosed in any region," per ClinicalTrials.gov ¹, ¹⁰.

At 52 weeks, BMI fell 15.84 percent on the drug and rose 2.55 percent on placebo ¹. The placebo-adjusted difference was -18.40 percentage points, confidence interval -21.94 to -14.85 ¹. A BMI loss of at least 10 percent was reached by 60.99 percent on the drug and 4.69 percent on placebo ¹. A loss of at least 15 percent was reached by 50.12 and 2.15 percent ¹. Among those aged 12 and older, the daily maximal hunger score fell more on the drug than on placebo, a difference of -0.82 points, confidence interval -1.62 to -0.02 ¹.

In children aged 2 to under 6, one open-label trial treated 12 patients for 52 weeks, three with POMC deficiency, four with LEPR deficiency and five with Bardet-Biedl syndrome ¹. Mean BMI fell 33.8, 13.1 and 9.7 percent in the three groups, with no placebo arm ¹. None of these trials tested setmelanotide in people with common obesity ¹.

What are the side effects?

The label lists the most common adverse reactions, those at 20 percent or more in at least one indication ¹. They are "skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection" ¹. In the placebo-controlled trial of acquired hypothalamic obesity, skin hyperpigmentation was reported in 58 percent on the drug and 10 percent on placebo ¹. Nausea was reported in 55 and 25 percent, vomiting in 38 and 19 percent, and new or darkened moles in 15 and 6 percent ¹. The published paper, of 120 participants, reports serious adverse events in 28 percent on the drug and 8 percent on placebo ⁴.

In the 27 people with POMC, PCSK1 or LEPR deficiency in the open-label trials, injection site reactions were reported in 96 percent and skin hyperpigmentation in 78 percent ¹. Depression was reported in 26 percent of them and suicidal ideation in 11 percent, with no placebo group to compare ¹. The published genetic-deficiency trials reported no serious treatment-related adverse events ³. In the Bardet-Biedl trial, two of the 38 had four serious adverse events, "blindness, anaphylactic reaction, and suicidal ideation" ⁵. The investigators considered none of them related to the drug, and five of the 38 stopped the study drug because of adverse events ⁵.

Skin darkening is the most common of the label's warnings in the trials ¹. The label says "Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients in clinical trials" and that "This effect is reversible upon discontinuation of the drug" ¹. The drug "may also cause the development of new melanocytic nevi or darkening of pre-existing nevi," nevi being moles ¹. The label directs a "full body skin examination prior to initiation and periodically during treatment" ¹.

Sexual adverse reactions are a second warning. "Spontaneous penile erections and increased frequency of penile erections in males occurred in clinical trials" ¹. They were reported in 23 percent of the 13 males in the genetic-deficiency trials and 25 percent of the 20 males in the Bardet-Biedl trial ¹. The label tells clinicians to "instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention" ¹.

The third warning is mood. "Some drugs that target the central nervous system, such as IMCIVREE, may cause depression or suicidal ideation" ¹. "Patients with a history of depression or suicidal ideation may be at increased risk for recurrent episodes" ¹. The label asks for monitoring of "new onset or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior" ¹.

"Serious hypersensitivity reactions, including anaphylaxis, have been reported," generally "within minutes to hours after injecting" ¹. The label contraindicates the drug after "a prior serious hypersensitivity reaction to setmelanotide or any of the excipients" ¹. On pregnancy, the label tells prescribers to "discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus" ¹.

Two warnings apply only to acquired hypothalamic obesity, and the label's heading for the first is "Acute Adrenal Insufficiency in Patients with Acquired HO," a sudden shortfall of the adrenal glands' hormones ¹. In patients who already had secondary adrenal insufficiency, "serious adverse reactions related to acute adrenal insufficiency were reported by 5% of IMCIVREE-treated patients and no placebo-treated patients" ¹. The second is "Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus," the last being a shortage of the water-balance hormone vasopressin ¹. In them, "hyponatremia was reported in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients, and hypernatremia was reported in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients," that is, low and high blood sodium ¹.

In sport

Setmelanotide is not named on WADA's 2026 Prohibited List ¹¹. WADA, the World Anti-Doping Agency, heads its section S2 "PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS," and setmelanotide is not among the substances it names ¹¹.

What JumpstartMD offers

JumpstartMD does not prescribe setmelanotide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.